Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial
Research article
[키워드] 28-day mortality
95% CI
age
baseline
Bioscience
Biotechnology
CKD
Clinical improvement
clinical trial
Controlled trial
Coronavirus disease 2019 (COVID-19)
COVID-19
COVID-19 patient
Day
death
Disseminated intravascular coagulation
Efficacy
enrolled
evaluated
finding
funding
group
groups
high-flow oxygen therapy
hospitalised patient
hospitalized patient
IQR
mechanical ventilation
median
median time
moderate
multicentre
nafamostat
Nafamostat mesilate
nasal
no significant difference
Non-invasive
Open-label
Oxygen treatment
Patient
patients
phase
Pneumonia
primary endpoint
Primary outcome
randomised
randomized clinical trial
Rate
Ratio
receiving
Registered
Russia
score
secondary outcome
serine protease inhibitor
Serious Adverse Event
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
severe COVID-19
significantly higher
Standard-of-care
the patient
Time to recovery
Treatment
Trial
was recorded
with COVID-19
[DOI] 10.1016/j.eclinm.2021.101169 [Article Type] Research article
[DOI] 10.1016/j.eclinm.2021.101169 [Article Type] Research article